Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2017-05-24 Capital/Financing Update
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Renounceable Issue 23 pages 2.1MB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Biotron Limited regarding a renounceable rights issue to raise capital, including terms of the offer, timetable, and use of proceeds. It also includes an extensive investor presentation with company background, clinical programs, financial metrics, and strategic outlook. The content focuses on financing activities and investor information rather than financial results or regulatory compliance filings. The presence of detailed financing terms and a capital raising plan indicates this is a Capital/Financing Update. The document length and detail confirm it is not a brief announcement or a simple report publication notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2017-05-24 English
Prospectus 41 pages 175.3KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Prospectus' and details a renounceable pro rata offer of new shares and options to existing shareholders, including the issue price, underwriting details, timetable, and use of proceeds. It is a formal offer document for raising capital through issuing new shares and options, which is characteristic of a capital raising or financing activity. There is no indication that this is a full annual or interim report, audit report, or other types of filings. The document is not a brief announcement but a detailed prospectus for a share issue. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length and content support a high confidence score.
2017-05-24 English
The Need for Drugs Targeting HIV-1 in Macophages 2 pages 67.1KB
Regulatory Filings Classification · 95% confidence The document is a letter dated 1 May 2017 from Biotron Limited to the ASX (Australian Securities Exchange) manager. It discusses recent independent research validating Biotron's drug development approach targeting HIV-1 in macrophages and provides updates on a Phase 2 clinical trial of their drug BIT225. The document is only 3845 characters long and appears to be a corporate announcement or update rather than a full financial or regulatory report. It does not contain financial statements, detailed financial analysis, or regulatory certifications. It is not an earnings release or annual/interim report. The content is primarily a corporate update on research and clinical trial progress, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories. The document is not a report publication announcement since it does not mention an attached report or provide a link to a report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2017-04-30 English
Appendix 4C - quarterly 5 pages 90.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed financial data including consolidated statements of cash flows for the current quarter and year to date, cash flow from operating, investing, and financing activities, payments to directors and related parties, financing facilities, estimated cash outflows for the next quarter, and a compliance statement signed by a director. The document is 8155 characters long, which is substantial and contains actual financial data and analysis for a quarterly period. The presence of detailed financial statements and cash flow information aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or certification but a full quarterly financial report. Therefore, the appropriate classification is IR (Interim / Quarterly Report). 9M 2017
2017-04-19 English
Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial 2 pages 42.4KB
Regulatory Filings Classification · 95% confidence The document is a company announcement providing an update on the progress of a Phase 2 clinical trial for the drug BIT225. It is a brief communication, only 3167 characters long, and does not contain any financial data, financial statements, or detailed analysis. It is not a report, transcript, or regulatory filing but rather a progress update on a clinical trial. The content is consistent with a general regulatory announcement or company update rather than a formal financial or governance report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements that do not fit other categories.
2017-04-10 English
Letter to Shareholders 3 pages 237.1KB
Regulatory Filings Classification · 95% confidence The document is titled 'SHAREHOLDER UPDATE' and is addressed to shareholders, containing detailed progress updates on clinical trials, research results, and company activities. It is a newsletter-style communication from the CEO and Managing Director, providing operational and developmental highlights rather than formal financial statements or regulatory filings. There is no indication of financial data, audit information, or regulatory compliance content. The document is not a formal report like an Annual Report (10-K) or Interim Report (IR), nor is it a presentation or call transcript. It is a shareholder communication update, which does not fit neatly into most categories but aligns best with Regulatory Filings (RNS) as a general announcement and update to shareholders that does not fall under other specific categories.
2017-02-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.